Description
Tirzepatide 10mg
This is a long-acting GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist that increases insulin sensitivity and secretion, suppresses glucagon secretion, and slows gastric emptying.
Weight management [in conjunction with dietary measures and increased physical activity in individuals with a BMI of 30 kg/m2 or more, or in individuals with a BMI of 27 kg/m2 or more in the presence of at least one weight-related co-morbidity]for tirzepatide
By subcutaneous injection
AdultInitially 2.5 mg once weekly for 4 weeks, then increased to 5 mg once weekly for at least 4 weeks, then increased if necessary up to 15 mg once weekly, dose to be increased in steps of 2.5 mg at intervals of at least 4 weeks. Assess benefit of continuing treatment if at least 5% of initial body-weight has not been lost after 6 months at highest tolerated dose.
Reviews
There are no reviews yet.